or Try an Advanced Search...

    Technical Analysis for EDSA - Edesa Biotech, Inc.

    Grade Last Price % Change Price Change
    C 4.51 -0.44% -0.02
    EDSA closed down 0.44 percent on Wednesday, May 15, 2024, on 5.14 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical EDSA trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Volume Surge Other 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    50 DMA Support Bullish -0.44%
    Crossed Above 20 DMA Bullish -0.44%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.44%
    Pocket Pivot Bullish Swing Setup -0.44%
    Bollinger Band Squeeze Range Contraction -0.44%
    Older End-of-Day Signals for EDSA ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 23 hours ago
    10 DMA Support about 23 hours ago
    Non-ADX 1,2,3,4 Pullback Entry about 23 hours ago
    Rose Above Previous Day's High about 23 hours ago
    Rose Above Upper Bollinger Band about 23 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    EDSA Chart by TradingView
    Basic chart:

    Profile

    Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Medication Dermatitis

    Is EDSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Edesa Biotech GAAP EPS of -$0.58 beats by $0.11
    May 10 Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
    Apr 11 Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
    Apr 2 Edesa Biotech to Participate in Upcoming Investor Conferences
    Mar 21 Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
    Mar 7 Edesa Biotech to Participate in Barclays Global Healthcare Conference
    Feb 15 EDSA: Development of EB05 in ARDS Continues…
    Feb 9 Edesa Biotech GAAP EPS of -$0.54 beats by $0.67
    Feb 9 Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
    Jan 4 Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
    See more EDSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.3331
    52 Week Low 0.3927
    Average Volume 6,962
    200-Day Moving Average 3.41
    50-Day Moving Average 4.42
    20-Day Moving Average 4.47
    10-Day Moving Average 4.53
    Average True Range 0.31
    RSI (14) 50.98
    ADX 19.48
    +DI 22.46
    -DI 18.77
    Chandelier Exit (Long, 3 ATRs) 3.95
    Chandelier Exit (Short, 3 ATRs) 5.05
    Upper Bollinger Bands 4.63
    Lower Bollinger Band 4.31
    Percent B (%b) 0.62
    BandWidth 7.22
    MACD Line 0.02
    MACD Signal Line 0.02
    MACD Histogram 0.0048
    Fundamentals Value
    Market Cap 14.3 Million
    Num Shares 3.17 Million
    EPS -20.51
    Price-to-Earnings (P/E) Ratio -0.22
    Price-to-Sales 120477.93
    Price-to-Book 2.17
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.96
    Resistance 3 (R3) 4.99 4.87 4.89
    Resistance 2 (R2) 4.87 4.76 4.86 4.86
    Resistance 1 (R1) 4.69 4.68 4.63 4.66 4.83
    Pivot Point 4.57 4.57 4.54 4.56 4.57
    Support 1 (S1) 4.39 4.46 4.33 4.36 4.19
    Support 2 (S2) 4.27 4.38 4.26 4.16
    Support 3 (S3) 4.09 4.27 4.14
    Support 4 (S4) 4.06